Ikena Oncology (IMA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Ikena Oncology is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.14) per share.
• The company's stock has seen a 4.5% decline and currently trades at $15.75, with a market cap of $63.32 million.
• Insider transactions reveal significant stock purchases, with Director Otello Stampacchia acquiring 267,556 shares at an average price of $29.90 per share.

Ikena Oncology (NASDAQ:IMA - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Ikena Oncology to post earnings of ($0.14) per share for the quarter.

Ikena Oncology (NASDAQ:IMA - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.08. On average, analysts expect Ikena Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ikena Oncology Trading Down 4.5%

Shares of Ikena Oncology stock opened at $15.75 on Thursday. The company has a fifty day simple moving average of $16.12 and a 200-day simple moving average of $15.73. The stock has a market cap of $63.32 million, a price-to-earnings ratio of -2.05 and a beta of 0.51. Ikena Oncology has a 12-month low of $11.65 and a 12-month high of $23.28.

Insider Transactions at Ikena Oncology

In other news, Director Otello Stampacchia acquired 267,556 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was acquired at an average cost of $29.90 per share, with a total value of $7,999,924.40. Following the completion of the acquisition, the director owned 454,982 shares of the company's stock, valued at $13,603,961.80. The trade was a 142.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David P. Bonita bought 83,611 shares of the stock in a transaction dated Friday, July 25th. The shares were acquired at an average price of $29.90 per share, for a total transaction of $2,499,968.90. Following the completion of the transaction, the director owned 287,885 shares of the company's stock, valued at approximately $8,607,761.50. The trade was a 40.93% increase in their position. The disclosure for this purchase can be found here. 5.94% of the stock is owned by corporate insiders.

Institutional Trading of Ikena Oncology

An institutional investor recently raised its position in Ikena Oncology stock. Goldman Sachs Group Inc. raised its holdings in Ikena Oncology, Inc. (NASDAQ:IMA - Free Report) by 62.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 76,464 shares of the company's stock after purchasing an additional 29,369 shares during the quarter. Goldman Sachs Group Inc. owned about 0.16% of Ikena Oncology worth $98,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 75.00% of the company's stock.

Analyst Ratings Changes

Separately, Wedbush reduced their price target on shares of Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating for the company in a research report on Friday, July 25th.

Ikena Oncology Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.